These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18242088)

  • 41. Tetrahydrobenzothiophene inhibitors of hepatitis C virus NS5B polymerase.
    Laporte MG; Lessen TA; Leister L; Cebzanov D; Amparo E; Faust C; Ortlip D; Bailey TR; Nitz TJ; Chunduru SK; Young DC; Burns CJ
    Bioorg Med Chem Lett; 2006 Jan; 16(1):100-3. PubMed ID: 16260131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives.
    Ismail MA; Abou El Ella DA; Abouzid KA; Mahmoud AH
    Bioorg Med Chem; 2012 Apr; 20(7):2455-78. PubMed ID: 22386565
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors.
    Rong F; Chow S; Yan S; Larson G; Hong Z; Wu J
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1663-6. PubMed ID: 17258458
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
    Xue W; Jiao P; Liu H; Yao X
    Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of a series of novel derivatives as potent HCV inhibitors by a ligand-based virtual screening optimized procedure.
    Melagraki G; Afantitis A; Sarimveis H; Koutentis PA; Markopoulos J; Igglessi-Markopoulou O
    Bioorg Med Chem; 2007 Dec; 15(23):7237-47. PubMed ID: 17869118
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preparation and biological evaluation of 1'-cyano-2'-C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors.
    Mish MR; Cho A; Kirschberg T; Xu J; Zonte CS; Fenaux M; Park Y; Babusis D; Feng JY; Ray AS; Kim CU
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3092-5. PubMed ID: 24907145
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
    Chen CM; He Y; Lu L; Lim HB; Tripathi RL; Middleton T; Hernandez LE; Beno DW; Long MA; Kati WM; Bosse TD; Larson DP; Wagner R; Lanford RE; Kohlbrenner WE; Kempf DJ; Pilot-Matias TJ; Molla A
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4290-6. PubMed ID: 17908950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moiety.
    Hutchinson DK; Flentge CA; Donner PL; Wagner R; Maring CJ; Kati WM; Liu Y; Masse SV; Middleton T; Mo H; Montgomery D; Jiang WW; Koev G; Beno DW; Stewart KD; Stoll VS; Molla A; Kempf DJ
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1876-9. PubMed ID: 21316235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design and synthesis of lactam-thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors.
    Barnes-Seeman D; Boiselle C; Capacci-Daniel C; Chopra R; Hoffmaster K; Jones CT; Kato M; Lin K; Ma S; Pan G; Shu L; Wang J; Whiteman L; Xu M; Zheng R; Fu J
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3979-85. PubMed ID: 24986660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha,gamma-diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis.
    Summa V; Petrocchi A; Matassa VG; Taliani M; Laufer R; De Francesco R; Altamura S; Pace P
    J Med Chem; 2004 Oct; 47(22):5336-9. PubMed ID: 15481971
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ligand-induced changes in hepatitis C virus NS5B polymerase structure.
    Rigat K; Wang Y; Hudyma TW; Ding M; Zheng X; Gentles RG; Beno BR; Gao M; Roberts SB
    Antiviral Res; 2010 Nov; 88(2):197-206. PubMed ID: 20813137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides.
    Chan L; Das SK; Reddy TJ; Poisson C; Proulx M; Pereira O; Courchesne M; Roy C; Wang W; Siddiqui A; Yannopoulos CG; Nguyen-Ba N; Labrecque D; Bethell R; Hamel M; Courtemanche-Asselin P; L'Heureux L; David M; Nicolas O; Brunette S; Bilimoria D; Bédard J
    Bioorg Med Chem Lett; 2004 Feb; 14(3):793-6. PubMed ID: 14741291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics.
    Beaulieu PL
    IDrugs; 2006 Jan; 9(1):39-43. PubMed ID: 16374732
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure.
    Yan S; Larson G; Wu JZ; Appleby T; Ding Y; Hamatake R; Hong Z; Yao N
    Bioorg Med Chem Lett; 2007 Jan; 17(1):63-7. PubMed ID: 17049849
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imidazopyridazine hepatitis C virus polymerase inhibitors. Structure-activity relationship studies and the discovery of a novel, traceless prodrug mechanism.
    Leivers M; Miller JF; Chan SA; Lauchli R; Liehr S; Mo W; Ton T; Turner EM; Youngman M; Falls JG; Long S; Mathis A; Walker J
    J Med Chem; 2014 Mar; 57(5):1964-75. PubMed ID: 24224729
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.
    Kim SH; Tran MT; Ruebsam F; Xiang AX; Ayida B; McGuire H; Ellis D; Blazel J; Tran CV; Murphy DE; Webber SE; Zhou Y; Shah AM; Tsan M; Showalter RE; Patel R; Gobbi A; LeBrun LA; Bartkowski DM; Nolan TG; Norris DA; Sergeeva MV; Kirkovsky L; Zhao Q; Han Q; Kissinger CR
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4181-5. PubMed ID: 18554907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives.
    Hutchinson DK; Rosenberg T; Klein LL; Bosse TD; Larson DP; He W; Jiang WW; Kati WM; Kohlbrenner WE; Liu Y; Masse SV; Middleton T; Molla A; Montgomery DA; Beno DW; Stewart KD; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3887-90. PubMed ID: 18599294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibitors of HCV NS5B polymerase. Part 2: Evaluation of the northern region of (2Z)-2-benzoylamino-3-(4-phenoxy-phenyl)-acrylic acid.
    Pfefferkorn JA; Nugent R; Gross RJ; Greene M; Mitchell MA; Reding MT; Funk LA; Anderson R; Wells PA; Shelly JA; Anstadt R; Finzel BC; Harris MS; Kilkuskie RE; Kopta LA; Schwende FJ
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2812-8. PubMed ID: 15911260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery and initial optimization of alkoxyanthranilic acid derivatives as inhibitors of HCV NS5B polymerase.
    Parcella K; Nickel A; Beno BR; Sheriff S; Wan C; Wang YK; Roberts SB; Meanwell NA; Kadow JF
    Bioorg Med Chem Lett; 2017 Jan; 27(2):295-298. PubMed ID: 27908764
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The discovery and structure-activity relationships of pyrano[3,4-b]indole-based inhibitors of hepatitis C virus NS5B polymerase.
    Jackson RW; LaPorte MG; Herbertz T; Draper TL; Gaboury JA; Rippin SR; Patel R; Chunduru SK; Benetatos CA; Young DC; Burns CJ; Condon SM
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3227-31. PubMed ID: 21550237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.